

Section 2112(b)(2) also provides that the special master “shall afford all interested persons an opportunity to submit relevant, written information” relating to the following:

1. The existence of evidence “that there is not a preponderance of the evidence that the illness, disability, injury, condition, or death described in the petition is due to factors unrelated to the administration of the vaccine described in the petition,” and

2. Any allegation in a petition that the petitioner either:

(a) “Sustained, or had significantly aggravated, any illness, disability, injury, or condition not set forth in the Table but which was caused by” one of the vaccines referred to in the Table, or

(b) “Sustained, or had significantly aggravated, any illness, disability, injury, or condition set forth in the Vaccine Injury Table the first symptom or manifestation of the onset or significant aggravation of which did not occur within the time period set forth in the Table but which was caused by a vaccine” referred to in the Table.

In accordance with Section 2112(b)(2), all interested persons may submit written information relevant to the issues described above in the case of the petitions listed below. Any person choosing to do so should file an original and three (3) copies of the information with the Clerk of the U.S. Court of Federal Claims at the address listed above (under the heading **FOR FURTHER INFORMATION CONTACT**), with a copy to HRSA addressed to Director, Division of Vaccine Injury Compensation Program, Healthcare Systems Bureau, 5600 Fishers Lane, Room 11C-26, Rockville, MD 20857. The Court’s caption (Petitioner’s Name v. Secretary of Health and Human Services) and the docket number assigned to the petition should be used as the caption for the written submission. Chapter 35 of title 44, United States Code, related to paperwork reduction, does not apply to information required for purposes of carrying out the Program.

Dated: June 24, 2013.

Mary K. Wakefield,
Administrator.

List of Petitions Filed

1. James Gordon Cook, Vinita, Oklahoma, Court of Federal Claims No: 13–0309V.
2. Brian Charles Jensen, Santa Clarita, California, Court of Federal Claims No: 13–0310V.
3. Sandy Richardson on behalf of Indy Gantt, Columbus, Ohio, Court of Federal Claims No: 13–0313V.
4. Brooke Searles, Torrance, California, Court of Federal Claims No: 13–0318V.
5. Alfonso Pacheco, New Fairfield, Connecticut, Court of Federal Claims No: 13–0322V.
6. Michael and Kimberly Prater on behalf of Christian M. Prater, Sheridan, Indiana, Court of Federal Claims No: 13–0325V.
7. Earleen Bean-Sasser, Eureka, California, Court of Federal Claims No: 13–0326V.
8. Michael G. Corcoran on behalf of S.R.C., Chagrin Falls, Ohio, Court of Federal Claims No: 13–0330V.
9. Daniella Castillo and Daniel Ruiz on behalf of D.R., Coral Gables, Florida, Court of Federal Claims No: 13–0333V.
10. Isabel Terrell, Palm Beach Gardens, Florida, Court of Federal Claims No: 13–0334V.
11. Teresa N. Gore, Loris, South Carolina, Court of Federal Claims No: 13–0335V.
12. Charlise Ellis on behalf of X’Von Godwin, Brentwood, New Jersey, Court of Federal Claims No: 13–0336V.
13. Brian Randall, Ventura, California, Court of Federal Claims No: 13–0337V.
14. Amy Cain, Charleston, West Virginia, Court of Federal Claims No: 13–0342V.
15. Marva Ross, Vienna, Virginia, Court of Federal Claims No: 13–0343V.
16. Jesse Knight, Gilbert, Arizona, Court of Federal Claims No: 13–0344V.
17. Christina and Greg Schniegenberg on behalf of Morgan Schniegenberg, Napa, California, Court of Federal Claims No: 13–0347V.
18. Glynis Lee, Houston, Texas, Court of Federal Claims No: 13–0348V.
19. Cristal Bello, Baraboo, Wisconsin, Court of Federal Claims No: 13–0349V.
20. Arlene Trompczynski, Oakland, California, Court of Federal Claims No: 13–0351V.
21. Glenn C. Ryan, St. Augustine, Florida, Court of Federal Claims No: 13–0354V.
22. Stacy and William Boula on behalf of Stephanie Boula, Rochester, New York, Court of Federal Claims No: 13–0356V.
24. Terry Lee Estvold, Federal Way, Washington, Court of Federal Claims No: 13–0358V.
25. Amanda LaCroix, San Antonio, Texas, Court of Federal Claims No: 13–0359V.
26. Timothy Woody and Carmen Verdugo-Woody on behalf of V. W., Homestead, Florida, Court of Federal Claims No: 13–0366V.

[FR Doc. 2013–15535 Filed 6–27–13; 8:45 am]

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Proposed Collection; 60-Day Comment Request; Family Life, Activity, Sun, Health, and Eating (FLASHE) Study (NCI)

Summary: In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the National Cancer Institute (NCI), National Institutes of Health (NIH), will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

To Submit Comments and For Further Information: To obtain a copy of the data collection plans and instruments, submit comments in writing, or request more information on the proposed project, contact: Linda Nebeling, Ph.D., Division of Cancer Control and Population Sciences, National Cancer Institute, 9609 Medical Center Drive, Room 3E102, Bethesda, MD 20892–9671 or call non-toll-free number 240–276–6855 or Email your request, including your address to: nebelinl@mail.nih.gov. Formal requests for additional plans and instruments must be requested in writing.

Comment Due Date: Comments regarding this information collection are best assured of having their full effect if

received within 60 days of the date of this publication.

Proposed Collection: Family Life, Activity, Sun, Health, and Eating (FLASHE) Study 0925—NEW, National Cancer Institute (NCI), National Institutes of Health (NIH).

Need and Use of Information Collection: The FLASHE study seeks to examine psychosocial, generational (parent-adolescent), and environmental correlates of cancer preventive behaviors. FLASHE will examine the

science of cancer and obesity prevention by examining correlates of cancer preventive behaviors, mainly diet, activity, and sedentary behaviors (but also examining other behaviors such as sleep, sun-safety, and tobacco) in new ways not previously addressed comprehensively on other surveys. The survey's goal is to advance understanding of the dynamic relationship between the environment, psychosocial factors, and behavior from a dyadic perspective. Data collected will

ultimately be a public use dataset and resource to the research community. FLASHE will be collecting data from parents and their adolescent children through a web survey with a final sample size of 2,500 dyads with motion sensing data collected in a subsample of 900 adolescents.

OMB approval is requested for two years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 1,931.

ESTIMATED ANNUALIZED BURDEN HOURS

Form name	Type of respondent	Number of respondents	Number of responses per respondent	Average burden per response (in hours)	Total annual burden hours
Enrollment	Parents (enrolling self)	1,250	1	5/60	104
	Parents (enrolling adolescent)	1,250	1	5/60	104
Web survey with demographics	Parents	1,250	1	20/60	417
	Adolescents	1,250	1	20/60	417
Web survey without demographics ...	Parents	1,250	1	15/60	313
	Adolescents	1,250	1	15/60	313
Wear Log	Adolescents	450	7	5/60	263

Dated: June 24, 2013.

Vivian Horovitch-Kelley,

NCI Project Clearance Liaison, National Institutes of Health.

[FR Doc. 2013-15541 Filed 6-27-13; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of General Medical Sciences; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of General Medical Sciences Special Emphasis Panel; Clinical Trials of Pain Treatment.

Date: July 19, 2013.

Time: 1:00 p.m. to 2:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Natcher Building, 45 Center Drive, Room 3An.18, Bethesda, MD 20892-4874, (Telephone Conference Call).

Contact Person: Brian R. Pike, Ph.D., Scientific Review Officer, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, 45 Center Drive, Room 3An.18K, Bethesda, MD 20892-4874, 301-594-3607, pikbr@mail.nih.gov.

Name of Committee: National Institute of General Medical Sciences Special Emphasis Panel; Review of K99 Grant Applications.

Date: July 23, 2013.

Time: 8:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Doubletree by Hilton Bethesda, 8120 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Robert Horowitz, Ph.D., Scientific Review Officer, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, 45 Center Drive, Room 3An.18I, Bethesda, MD 20892-4874, 301-594-6904, horowitr@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.375, Minority Biomedical Research Support; 93.821, Cell Biology and Biophysics Research; 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.862, Genetics and Developmental Biology Research; 93.88, Minority Access to Research Careers; 93.96, Special Minority Initiatives, National Institutes of Health, HHS)

Dated: June 24, 2013.

Melanie J. Gray,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013-15450 Filed 6-27-13; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Time-Sensitive Obesity Research.

Date: July 15, 2013.

Time: 11:00 a.m. to 12:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Michele L. Barnard, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 753, 6707 Democracy Boulevard,